Literature DB >> 8639167

Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines.

.   

Abstract

RA is a chronic progressive polyarthritis (with varying systemic features) associated with substantial disability and economic losses. Successful treatment to limit joint damage and functional loss requires early diagnosis and timely initiation of disease-modifying agents. The goal of treatment is to arrest the disease and to achieve remission. Although remission rarely occurs, patients may still benefit from pharmacologic, nonpharmacologic, and if necessary, surgical interventions. Optimal longitudinal treatment requires comprehensive coordinated care and the expertise of a number of providers. Essential components of management include 1) establishment of the diagnosis of RA (versus other forms of polyarthritis), 2) systematic and regular evaluation of disease activity, 3) patient education/rehabilitation interventions, and initial treatment with NSAIDs, 4) use of DMARDs, 5) possible use of local or low-dose oral glucocorticoids, 6) minimization of the impact on the individual's function, 7) assessment of the adequacy of the treatment program, and 8) general health maintenance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8639167

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  61 in total

1.  Individualized stepped care of chronic illness.

Authors:  M Von Korff; B Tiemens
Journal:  West J Med       Date:  2000-02

2.  Role of mucus reduction and luminal acid elevation in increased susceptibility of stomach to nonsteroidal antiinflammatory drug-induced injury in arthritic rats.

Authors:  K Okuyama; M Jinbo; N Saito; S Igarashi; H Narita; M Kinoshita
Journal:  Dig Dis Sci       Date:  2000-11       Impact factor: 3.199

Review 3.  Rheumatology: 8. Advanced therapy.

Authors:  D Lacaille
Journal:  CMAJ       Date:  2000-09-19       Impact factor: 8.262

Review 4.  Rheumatology: 7. Basics of therapy.

Authors:  S H Huang
Journal:  CMAJ       Date:  2000-08-22       Impact factor: 8.262

Review 5.  [Update of rheumatology--II. State and prospectives of chemotherapy in chronic arthritis].

Authors:  G Hein; T Eidner; P Oelzner; B Manger
Journal:  Med Klin (Munich)       Date:  1999-10-15

Review 6.  Leflunomide: a review of its use in active rheumatoid arthritis.

Authors:  A Prakash; B Jarvis
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

Review 7.  [Drug therapy of rheumatoid arthritis].

Authors:  U Arndt; M Rittmeister; B Möller
Journal:  Orthopade       Date:  2003-12       Impact factor: 1.087

8.  Public health impact of risk factors for physical inactivity in adults with rheumatoid arthritis.

Authors:  Jungwha Lee; Dorothy Dunlop; Linda Ehrlich-Jones; Pamela Semanik; Jing Song; Larry Manheim; Rowland W Chang
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-04       Impact factor: 4.794

Review 9.  Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.

Authors:  Michael T Nurmohamed; Ben A C Dijkmans
Journal:  Drugs       Date:  2005       Impact factor: 9.546

10.  Leflunomide in active rheumatoid arthritis: a prospective study in daily practice.

Authors:  E N Van Roon; T L Th A Jansen; L Mourad; P M Houtman; G A W Bruyn; E N Griep; B Wilffert; H Tobi; J R B J Brouwers
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.